Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay

Mitchell J. Elliott (), Philippe Echelard, Christodoulos Pipinikas, Sasha Main, Jesús Fuentes Antrás, Aaron Dou, Zachary Veitch, Eitan Amir, Michelle B. Nadler, Nicholas Meti, Eshetu Atenafu, Elizabeth Shah, Celeste Yu, Nathan Campbell, Robert Ventura, Lillian L. Siu, Philippe L. Bedard, Hal K. Berman and David W. Cescon ()
Additional contact information
Mitchell J. Elliott: Princess Margaret Cancer Centre and University of Toronto
Philippe Echelard: Université de Sherbrooke
Christodoulos Pipinikas: NeoGenomics, Babraham Research Campus
Sasha Main: University of Toronto
Jesús Fuentes Antrás: Hospital Universitario Quirónsalud
Aaron Dou: Princess Margaret Cancer Centre and University of Toronto
Zachary Veitch: Royal Victoria Regional Health Centre
Eitan Amir: Princess Margaret Cancer Centre and University of Toronto
Michelle B. Nadler: Princess Margaret Cancer Centre and University of Toronto
Nicholas Meti: McGill University
Eshetu Atenafu: University Health Network
Elizabeth Shah: Princess Margaret Cancer Centre and University of Toronto
Celeste Yu: Princess Margaret Cancer Centre and University of Toronto
Nathan Campbell: NeoGenomics, Babraham Research Campus
Robert Ventura: NeoGenomics, Babraham Research Campus
Lillian L. Siu: Princess Margaret Cancer Centre and University of Toronto
Philippe L. Bedard: Princess Margaret Cancer Centre and University of Toronto
Hal K. Berman: University Health Network
David W. Cescon: Princess Margaret Cancer Centre and University of Toronto

Nature Communications, 2025, vol. 16, issue 1, 1-13

Abstract: Abstract Circulating tumor DNA (ctDNA) is an emerging biomarker for the treatment of early breast cancer (EBC). We sought to evaluate a highly sensitive tumor-informed ctDNA assay in a real-world cohort of patients receiving neoadjuvant therapy (NAT) to assess clinical validity and explore prognostic outcomes. ctDNA is detected in 77.2% (88/114) of participants at baseline, with 18/88 (20.5%) having a baseline estimated variant allele frequency (eVAF) of

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-56658-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56658-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-56658-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().